Press Release
simAbs and Ardent Biopharma Announce Exclusive Strategic Partnership to Advance Next-Generation Biosimilar Manufacturing
Hasselt, Belgium & Leiden, The Netherlands – April 7th, 2026
simAbs NV and Ardent Biopharma BV today announced an exclusive strategic development partnership focused on the development of two monoclonal antibody biosimilars, AB01 and AB02, using next-generation continuous manufacturing technologies…
SimAbs Raises €5 Million Series A to Scale Continuous GMP Manufacturing and expand current development for Antibodies and Biosimilars: Cells in, Drug Substance out.
Diepenbeek, BioVille, Belgium, December 18, 2025 – SimAbs is proud to announce the successful closing of a €5 million Series A financing round. This investment marks a major step in the…